Although PET/CT scans are rarely used for monitoring ICC treatment, the essential role of the FGFR2/MEK/ERK pathway in glucose uptake in FGFR2 + ICC may help in assessing therapeutic response. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.